Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)				6 Months Ended	9 Months Ended
	Oct. 07, 2025 USD ($)	Sep. 29, 2025	Sep. 19, 2025	Jun. 30, 2025 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number of Tumor Samples					150,000
Number of Reportable Segments					1
Retained Earnings (Accumulated Deficit)				$ (184,939,606)	$ (262,591,449)			$ (180,426,271)
Cash and Cash Equivalent				506,078	181,667			611,822
Liabilities, Current				3,845,439	79,488,676			3,593,401
Operating Lease, Liability, Noncurrent				1,243,327	1,076,544			1,558,239
Net Cash Provided by (Used in) Operating Activities, Continuing Operations				(4,280,632)	(5,934,497)	$ (8,049,679)
Equity, Attributable to Parent				$ (1,653,400)	$ (77,427,922)	$ 1,966,969	$ (145,796)	$ (202,610)	$ 4,093,971	$ 4,053,671	$ 8,271,780
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		15	15		15
Subsequent Event [Member]
Proceeds from Issuance of Private Placement	$ 50,800,000